dc.contributor.author | Sojka, Ladislav | |
dc.contributor.author | Opattová, Alena | |
dc.contributor.author | Bartu, Linda | |
dc.contributor.author | Horák, Josef | |
dc.contributor.author | Korenková, Vlasta | |
dc.contributor.author | Novosadova, Vendula | |
dc.contributor.author | Křížková, Věra | |
dc.contributor.author | Brůha, Jan | |
dc.contributor.author | Liška, Václav | |
dc.contributor.author | Schneiderová, Michaela | |
dc.contributor.author | Kubeček, Ondřej | |
dc.contributor.author | Vodičková, Ludmila | |
dc.contributor.author | Urbanova, Marketa | |
dc.contributor.author | Simsa, Jaromir | |
dc.contributor.author | Vodička, Pavel | |
dc.contributor.author | Vymetálková, Veronika | |
dc.date.accessioned | 2023-06-27T12:40:22Z | |
dc.date.available | 2023-06-27T12:40:22Z | |
dc.date.issued | 2023 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14178/1956 | |
dc.description.abstract | MUC13, a transmembrane mucin glycoprotein, is overexpressed in colorectal cancer (CRC), however, its regulation and functions are not fully understood. It has been shown that MUC13 protects colonic epithelial cells from apoptosis. Therefore, studying MUC13 and MUC13-regulated pathways may reveal promising therapeutic approaches for CRC treat- ment. Growing evidence suggests that microRNAs (miRs) are involved in the development and progression of CRC. In the present study, the MUC13-miR-4647 axis was addressed in association with survival of patients. miR-4647 is predicted in silico to bind to the MUC13 gene and was analyzed by RT-qPCR in 187 tumors and their adjacent non-malignant mucosa of patients with CRC. The impact of previously mentioned genes on survival and migration abilities of cancer cells was validated in vitro. Significantly upregulated MUC13 (P=0.02) in was observed tumor tissues compared with non-malignant adjacent mucosa, while miR-4647 (P=0.05) showed an opposite trend. Higher expression levels of MUC13 (log-rank P=0.05) were associated with worse patient's survival. The ectopic overexpression of studied miR resulted in decreased migratory abilities and worse survival of cells. Attenuated MUC13 expression levels confirmed the suppression of colony forming of CRC cells. In summary, the present data suggested the essential role of MUC13-miR-4647 in patients' survival, and this axis may serve as a novel thera- peutic target. It is anticipated MUC13 may hold significant potential in the screening, diagnosis and treatment of CRC. | en |
dc.language.iso | en | |
dc.relation.url | https://www.spandidos-publications.com/10.3892/ol.2022.13658 | |
dc.rights | Creative Commons Uveďte původ-Neužívejte dílo komerčně-Nezpracovávejte 4.0 International | cs |
dc.rights | Creative Commons Attribution-NonCommercial-NoDerivativeWorks 4.0 International | en |
dc.title | MUC13-miRNA-4647 axis in colorectal cancer: Prospects to identifications of risk factors and clinical outcomes | en |
dcterms.accessRights | openAccess | |
dcterms.license | https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode | |
dc.date.updated | 2024-01-22T20:10:38Z | |
dc.subject.keyword | colorectal cancer risk and clinical outcomes | en |
dc.subject.keyword | microRNA | en |
dc.subject.keyword | MUC13 | en |
dc.subject.keyword | translation research | en |
dc.relation.fundingReference | info:eu-repo/grantAgreement/FN/I-FN/I-FNP-04 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/GA0/GA/GA16-05942S | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MZ0/NV/NV19-09-00237 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MSM//LX22NPO5102 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/UK/COOP/COOP | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/FN/I-FN/I-FNHK | |
dc.date.embargoStartDate | 2024-01-22 | |
dc.type.obd | 73 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | |
dc.identifier.doi | 10.3892/ol.2022.13658 | |
dc.identifier.utWos | 000915155300001 | |
dc.identifier.eidScopus | 2-s2.0-85146013482 | |
dc.identifier.obd | 621323 | |
dc.identifier.pubmed | 36688110 | |
dc.subject.rivPrimary | 30000::30100::30106 | |
dc.subject.rivSecondary | 10000::10600 | |
dcterms.isPartOf.name | Oncology Letters | |
dcterms.isPartOf.issn | 1792-1074 | |
dcterms.isPartOf.journalYear | 2023 | |
dcterms.isPartOf.journalVolume | 25 | |
dcterms.isPartOf.journalIssue | 2 | |
uk.faculty.primaryId | 111 | |
uk.faculty.primaryName | Lékařská fakulta v Plzni | cs |
uk.faculty.primaryName | Faculty of Medicine in Pilsen | en |
uk.faculty.secondaryId | 108 | |
uk.faculty.secondaryId | 54 | |
uk.faculty.secondaryId | 51 | |
uk.faculty.secondaryId | 110 | |
uk.faculty.secondaryId | 112 | |
uk.faculty.secondaryName | 1. lékařská fakulta | cs |
uk.faculty.secondaryName | First Faculty of Medicine | en |
uk.faculty.secondaryName | Fakultní nemocnice Plzeň | cs |
uk.faculty.secondaryName | University Hospital in Pilsen | en |
uk.faculty.secondaryName | Fakultní nemocnice Hradec Králové | cs |
uk.faculty.secondaryName | University Hospital Hradec Králové | en |
uk.faculty.secondaryName | 3. lékařská fakulta | cs |
uk.faculty.secondaryName | Third Faculty of Medicine | en |
uk.faculty.secondaryName | Lékařská fakulta v Hradci Králové | cs |
uk.faculty.secondaryName | Faculty of Medicine in Hradec Kralove | en |
uk.department.primaryId | 100012968318 | |
uk.department.primaryName | Biomedicínské centrum | cs |
uk.department.primaryName | Biomedical Center | en |
uk.department.secondaryId | 5000000012 | |
uk.department.secondaryId | 1399 | |
uk.department.secondaryId | 1535 | |
uk.department.secondaryId | 1539 | |
uk.department.secondaryId | 1352 | |
uk.department.secondaryId | 700 | |
uk.department.secondaryId | 1445 | |
uk.department.secondaryId | 575 | |
uk.department.secondaryId | 623 | |
uk.department.secondaryId | 5000002701 | |
uk.department.secondaryName | Klinika onkologie a radioterapie | cs |
uk.department.secondaryName | Department of Oncology and Radiotherapy | en |
uk.department.secondaryName | Chirurgická klinika | cs |
uk.department.secondaryName | Department of Surgery | en |
uk.department.secondaryName | Ústav biologie a lékařské genetiky 1. LF UK a VFN | cs |
uk.department.secondaryName | Institute of Biology and Medical Genetics | en |
uk.department.secondaryName | Ústav imunologie a mikrobiologie 1. LF UK a VFN | cs |
uk.department.secondaryName | Institute of Immunology and Microbiology | en |
uk.department.secondaryName | Ústav histologie a embryologie | cs |
uk.department.secondaryName | Department of Histology and Embryology | en |
uk.department.secondaryName | Klinika onkologie a radioterapie | cs |
uk.department.secondaryName | Department of Oncology and Radiotherapy | en |
uk.department.secondaryName | Chirurgická klinika 1. LF UK a FTN | cs |
uk.department.secondaryName | Department of Surgery | en |
uk.department.secondaryName | Ústav lékařské genetiky 3. LF UK | cs |
uk.department.secondaryName | Department of Medical Genetics 3FM CU | en |
uk.department.secondaryName | Chirurgická klinika 3. LF UK a FNKV | cs |
uk.department.secondaryName | Department of General Surgery 3FM CU and UHKV | en |
uk.department.secondaryName | Chirurgická klinika | cs |
uk.department.secondaryName | Department of Surgery | en |
dc.type.obdHierarchyCs | ČLÁNEK V ČASOPISU::článek v časopisu::původní článek | cs |
dc.type.obdHierarchyEn | JOURNAL ARTICLE::journal article::original article | en |
dc.type.obdHierarchyCode | 73::152::206 | en |
uk.displayTitle | MUC13-miRNA-4647 axis in colorectal cancer: Prospects to identifications of risk factors and clinical outcomes | en |